Global Advanced Molecular Nuclear Imaging Market

The Global Advanced Molecular Nuclear Imaging Market Size was worth around USD 5.37 Billion in 2024 and is predicted to grow to around USD 9.60 Billion by 2035 with a compound annual growth rate (CAGR) of 5.42% from 2025 and 2035. The market for advanced molecular nuclear imaging has a number of opportunities to grow due to the adoption of advancements (PET/CT, SPECT/CT) and expanding infrastructure & investment.

Market Overview

The global advanced molecular nuclear imaging industry encompasses the high-precision, non-invasive diagnostic technologies, specifically PET and SPECT combined with CT or MRI to visualize biological processes at the cellular level, primarily for oncology, cardiology, and neurology. An increasing need for early disease detection, AI integration, and targeted radiopharmaceuticals is driving the growth of the advanced molecular nuclear imaging market for personalized medicine and improved patient outcomes. Advanced molecular nuclear imaging allows visualizing patients at the cellular and molecular levels for locating the disease, better understanding disease pathways, improving therapy selection, and monitoring patient response to treatment.

Innovation and market expansion are anticipated as a result of major players' growing R&D expenditures and the expanding partnerships. For instance, in March 2026, MedGenome announced a majority investment in Mumbai-headquartered Medcare Management Services Pvt. Ltd., a radiology and nuclear medicine company known for its PET-CT and advanced molecular imaging services.